iShares Global Healthcare ETF
Value per share
$76.60
if its companies were priced at our values from their reports
Last close
$114.77
Nov 13, 2026
49.8% above its value value
52 of 124 holdings valued70% of the fund
If the companies in IXJ were priced at the values we work out from their own financial reports, one share would be worth about $76.60. It last closed at $114.77. Read the other way, that is the same gap: the value is 33.3% below the price.
What the fund holds
5% priced below value 65% priced above value30% not valued
20% of the fund is in companies with a rough estimate (marked ! below).
What moves the number
How IXJ gets from its last close of $114.77 to its value of $76.60. Each bar starts where the previous one ends. A company priced above its value pulls the number down; one priced below it pushes the number up. Holdings we do not value leave it where it is.
- Last close$114.77
- Eli Lilly & Co−$10.82
- Johnson & Johnson−$5.25
- AbbVie Inc.−$3.25
- Merck & Co., Inc.−$2.52
- Thermo Fisher Scientific Inc.−$2.52
- All other holdings−$13.81
- Value per share$76.60
The steps add up to the $38.17 gap between the last close and the value.
Largest holdings
Showing 10 of 124 holdings.
| Company | Share of fund | Last close | Fair value | Gap | Effect |
|---|---|---|---|---|---|
Eli Lilly & CoLLY Rough estimate | 11.7% | $1,445 | $276.68 | 422.2% above | −$10.82 |
| 7.0% | $285.96 | $99.76 | 186.7% above | −$5.25 | |
AbbVie Inc.ABBV | 5.3% | $295.00 | $138.09 | 113.6% above | −$3.25 |
| 4.2% | $147.76 | $70.51 | 109.6% above | −$2.52 | |
| 3.8% | $407.52 | $374.54 | 8.8% above | −$0.35 | |
ROCHE HOLDING AGNot valued: not a U.S.-listed stock | 3.3% | – | – | – | – |
NOVARTIS AGNot valued: not a U.S.-listed stock | 3.3% | – | – | – | – |
ASTRAZENECA PLCAZN · Not valued: not on our list of companies | 3.3% | $184.46 | – | – | – |
| 3.0% | $700.18 | $187.16 | 274.1% above | −$2.52 | |
Amgen IncAMGN | 2.9% | $465.55 | $357.36 | 30.3% above | −$0.77 |
| 2.4% | $168.04 | $97.44 | 72.5% above | −$1.16 | |
Abbott LaboratoriesABT Rough estimate | 2.2% | $108.51 | $40.83 | 165.8% above | −$1.56 |
Pfizer IncPFE · Not valued: too few usable years of reports | 1.9% | $28.90 | – | – | – |
Intuitive Surgical IncISRG Rough estimate | 1.8% | $443.47 | $176.06 | 151.9% above | −$1.25 |
NOVO NORDISK A SNot valued: not a U.S.-listed stock | 1.8% | – | – | – | – |
Danaher CorpDHR Rough estimate | 1.7% | $232.99 | $44.62 | 422.1% above | −$1.57 |
| 1.6% | $538.54 | $246.11 | 118.8% above | −$0.98 | |
| 1.5% | $1,104 | $721.84 | 52.9% above | −$0.61 | |
| 1.5% | $102.86 | $48.86 | 110.5% above | −$0.92 | |
| 1.5% | $63.42 | $67.67 | 6.3% below | +$0.11 | |
| 1.3% | $89.35 | $171.11 | 47.8% below | +$1.38 | |
Stryker CorpSYK | 1.2% | $309.64 | $146.54 | 111.3% above | −$0.74 |
GSK PLCNot valued: not a U.S.-listed stock | 1.2% | – | – | – | – |
| 1.1% | $955.65 | $527.63 | 81.1% above | −$0.56 | |
| 1.1% | $429.63 | $609.12 | 29.5% below | +$0.51 | |
SANOFINot valued: not a U.S.-listed stock | 1.0% | – | – | – | – |
BLACKROCK CASH FUNDS INSTITUTIONAL FUND SL AGENCYCash collateral for shares the fund lent out; it is owed back | 0.9% | – | – | – | – |
Cigna GroupCI · Not valued: too few usable years of reports | 0.9% | $297.01 | – | – | – |
| 0.9% | $498.88 | $366.05 | 36.3% above | −$0.27 | |
| 0.8% | $359.02 | $195.81 | 83.4% above | −$0.42 | |
Boston Scientific CorpBSX Rough estimate | 0.8% | $44.35 | $29.34 | 51.2% above | −$0.29 |
| 0.8% | $281.10 | $159.42 | 76.3% above | −$0.38 | |
| 0.7% | $107.19 | $49.08 | 118.4% above | −$0.44 | |
| 0.7% | $218.05 | $138.46 | 57.5% above | −$0.29 | |
ARGENX SENot valued: not a U.S.-listed stock | 0.7% | – | – | – | – |
| 0.6% | $704.46 | $184.66 | 281.5% above | −$0.54 | |
ESSILORLUXOTTICA SANot valued: not a U.S.-listed stock | 0.6% | – | – | – | – |
BAYER AGNot valued: not a U.S.-listed stock | 0.6% | – | – | – | – |
Humana IncHUM Rough estimate | 0.6% | $450.47 | $785.38 | 42.6% below | +$0.53 |
HOYA CORPNot valued: not a U.S.-listed stock | 0.6% | – | – | – | – |
TAKEDA PHARMACEUTICAL CO LTDNot valued: not a U.S.-listed stock | 0.6% | – | – | – | – |
| 0.6% | $173.91 | $33.24 | 423.2% above | −$0.52 | |
LONZA GROUP AGNot valued: not a U.S.-listed stock | 0.5% | – | – | – | – |
| 0.5% | $301.68 | $154.22 | 95.6% above | −$0.29 | |
Waters CorpWAT · Not valued: too few usable years of reports | 0.5% | $460.58 | – | – | – |
| 0.5% | $265.03 | $112.81 | 134.9% above | −$0.34 | |
GALDERMA GROUP AGNot valued: not a U.S.-listed stock | 0.5% | – | – | – | – |
HALEON PLCNot valued: not a U.S.-listed stock | 0.5% | – | – | – | – |
SANDOZ GROUP AGNot valued: not a U.S.-listed stock | 0.5% | – | – | – | – |
CSL LTDNot valued: not a U.S.-listed stock | 0.4% | – | – | – | – |
| 0.4% | $83.05 | $48.77 | 70.3% above | −$0.21 | |
Biogen Inc.BIIB | 0.4% | $253.51 | $75.06 | 237.8% above | −$0.35 |
ALCON INCALC · Not valued: not on our list of companies | 0.4% | $74.13 | – | – | – |
UCB SANot valued: not a U.S.-listed stock | 0.4% | – | – | – | – |
Zoetis Inc.ZTS | 0.4% | $83.82 | $62.83 | 33.4% above | −$0.12 |
| 0.4% | $1,740 | $462.21 | 276.3% above | −$0.34 | |
Resmed IncRMD | 0.4% | $239.53 | $144.44 | 65.8% above | −$0.18 |
OTSUKA HOLDINGS CO LTDNot valued: not a U.S.-listed stock | 0.4% | – | – | – | – |
Centene CorpCNC Rough estimate | 0.4% | $71.28 | $221.02 | 67.7% below | +$0.93 |
Dexcom IncDXCM Rough estimate | 0.4% | $83.28 | $27.42 | 203.7% above | −$0.28 |
Share of fund: how much of the fund is in the company. Gap: the company's last close compared with the value we work out from its reports. Effect: how much the company moves the value of one IXJ share. Rough estimate (!): our value is far from the market price, probably because the reports miss something, like fast growth. We still use it. Not valued: we do not put a number on the company; it counts at its market price, so it does not move the value.
How we got this number
- Look insideWe read the fund's latest holdings report to the SEC, for June 30, 2026. It lists 124 holdings.
- Value each companyFor each company we value, we use the value we work out from its own financial reports instead of its stock price. That covers 52 of the holdings, 70% of the fund.
- Add it back upEverything else (cash, bonds and companies we do not value) stays at its market price. Added back up and split per share, one IXJ share comes to $76.60.
Good to know
- Funds report their holdings about two months after each quarter ends, so the list can be a few months old and recent changes are missed.
- If a stock's price is now more than 3 times higher or lower than on the report date (often after a stock split), it keeps its reported value.
- We value a fund only when we can value at least 70% of it, it holds at least $500 million, its report is less than 9 months old, and it does not bet against stocks or use more than a little in derivatives.
- We start from the fund's own last price, so if the fund trades a little above or below its holdings, that carries into the value.
- Why most funds come out above their value: our values use only what companies have already reported, including how fast they have grown so far. Investors often pay for faster growth than that, or are happy with a smaller yearly gain than our values assume.
- Most of the stocks we value (85%) trade above the values we work out from their reports, so most funds come out above their value too. That is how our method sees today's market, not a verdict on any one fund. It is not a forecast or a recommendation.
Technical details
The formula: value per share = last close × (1 + the sum over valued holdings of share of fund × (value ÷ last close − 1)). Each holding's share of the fund is measured against the fund's net assets at today's closes. Cash the fund holds as collateral for shares it has lent out is listed in its report but is owed back, so it does not count toward the fund's size.
- Net assets, all share classes, Jun 30, 2026
- $3.8B
- Net assets at today's closes
- $4.3B
- Holdings in the report
- 124
- Matched to a ticker
- 62
- Valued
- 52
- Short positions and derivatives
- 0.02% of net assets
- Price against value
- +49.8%
- Value against last close
- -33.3%
- SEC series
- S000004372
- Filing (accession)
- 0001004726-26-007010
Delayed quote
Delayed price and chart from TradingView. This site does not receive or store these prices, and the value per share above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.
Sources. Holdings: SEC Form N-PORT for the period ended June 30, 2026 (accession 0001004726-26-007010). Company values: this site's filings-based values (Nov 14, 2026). Closing prices: IEX Historical Data (Nov 13, 2026).